At Synoxmedicals we understand the power of being in control of your own journey in the treatment of your disease.
Our mission is to establish emactuzumab as a best-in-class drug of choice to address the unmet needs, and improve the quality of life, of as many patients as possible.
By connecting our industry-leading knowledge and experience with passion and dedication, we aim to provide life-improving options to address the unmet clinical needs of people living with tenosynovial giant cell tumours (TGCT) and other macrophage mediated diseases.
Synoxmedicals is led by an experienced team of industry professionals with a successful track record of developing and bringing products to commercialisation. It is backed by a strong syndicate of premier life sciences investors.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip.
EN 
UA